Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.
Heart damage is prevalent in COVID-19 patients, leading many to doubt how the virus impacts the heart.
Cas7-11, the first CRISPR enzyme that can make precise, directed cuts to strands of RNA without hurting cells, was identified and described last year by researchers at MIT’s McGovern Institute for Brain Research.
According to research published in eLife, researchers have developed a pipeline for detecting, prioritizing, and testing potential tumor antigens for the rapid development of cancer vaccines.
A new type of CRISPR platform that leverages the benefits of a compact RNA-editing protein could result in enhanced diagnostic tests for COVID-19.
Newly devised gene therapy can help children born with AADC, a rare genetic disorder that causes developmental and physical disabilities.
Children with a devastating genetic disorder characterized by severe motor disability and developmental delay have experienced sometimes dramatic improvements in a gene therapy trial launched at UCSF Benioff Children's Hospitals.
Cancer immunotherapy involves the activation of cells in the patient’s own immune system to fight tumor cells.
A new study shows that the advantageous effects of gene therapy can be observed several decades after the body clears the transplanted blood stem cells.
A tiny population of neurons known to be important to appetite appear to also have a significant role in depression that results from unpredictable, chronic stress, scientists say.
A new study performed by the IBMCP of UPV University enables the use of the CRISPR genomic editing technique on plants.